Weight loss drug Wegovy may prevent heart attacks.
Weight loss drug Wegovy may prevent heart attacks.
New Study Finds Weight Loss Drug Wegovy Reduces Heart Problems by 20%
Aug. 8, 2023 – A recent trial conducted on over 17,000 individuals with overweight or obesity and cardiovascular disease has revealed that the popular weight loss drug Wegovy successfully reduced heart attacks, strokes, and related deaths by 20%. This groundbreaking finding could potentially improve patient access to the drug, as it offers broader health benefits beyond just weight loss.
The trial, which was sponsored by Wegovy maker Novo Nordisk, involved participants who received 2.4-milligram shots of semaglutide, the active ingredient in Wegovy. The results showed a significant reduction in heart-related issues, including heart-related deaths, heart attacks, and strokes. Furthermore, the frequency of these problems occurring was also notably decreased.
Semaglutide belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) agonists and has previously been approved by the FDA as Wegovy for weight loss and as Ozempic for blood sugar control in individuals with type 2 diabetes. These findings highlight the potential of semaglutide to treat both weight-related issues and cardiovascular disease, opening up new avenues for patient care and treatment options.
The study has received positive feedback from experts in the field of metabolic medicine, including Naveed Sattar, a professor at the University of Glasgow in Scotland. Sattar expressed excitement over the trial’s results, emphasizing the importance of preventing heart attacks and strokes while simultaneously aiding weight loss. He also speculated that the associated weight loss could lead to a meaningful improvement in patients’ quality of life, but noted that further data is needed to determine the specific role weight loss played in the observed reduction of cardiovascular events.
Interestingly, these findings challenge the long-standing prejudice against weight loss drugs. Previously, there was skepticism surrounding the medical necessity and safety of such drugs solely for weight loss purposes. However, this trial demonstrates that Wegovy’s impact goes beyond weight reduction, potentially changing the way obesity is regarded in the medical community.
- Newly discovered genes and their role in obesity
- Can a bodybuilding supplement prevent dementia?
- Pecans may protect against obesity and diabetes.
Martin Holst Lange, the Executive Vice President for Development at Novo Nordisk, highlighted the significance of this study by stating that there are currently no approved weight management medications proven to simultaneously deliver effective weight management and reduce the risk of heart attacks, strokes, or cardiovascular death. The history of adverse effects associated with previous weight loss treatments led to caution among doctors and hindered health insurance coverage for weight loss treatments. For example, Medicare has long-standing policies against reimbursing the cost of medications used for weight loss, and federal laws have limited coverage in Part D plans since 2003.
This groundbreaking trial opens up possibilities for a shift in how weight loss treatments are perceived and covered by insurance providers. The results offer hope for individuals struggling with weight management and cardiovascular issues, as Wegovy presents a potential solution that addresses both concerns simultaneously.
Novo Nordisk plans to release a comprehensive report on the trial’s results during a scientific meeting later this year. This report will provide more detailed information and further insights into the efficacy and safety of Wegovy as a weight loss medication with additional cardiovascular benefits.
Overall, this study represents a significant step forward in the treatment of obesity and cardiovascular disease. By demonstrating the potential of Wegovy to reduce heart problems while aiding weight loss, patients can look forward to improved access to this medication, and the medical community can reconsider the value and safety of weight loss drugs in promoting overall health and well-being.
